Personalis, Inc. (NASDAQ:PSNL) Receives $24.33 Consensus Price Target from Brokerages

Personalis, Inc. (NASDAQ:PSNLGet Rating) has earned a consensus rating of “Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $24.33.

PSNL has been the subject of several analyst reports. HC Wainwright decreased their price objective on shares of Personalis from $38.00 to $30.00 in a research note on Thursday, May 5th. Oppenheimer decreased their price target on shares of Personalis from $30.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 25th. Citigroup decreased their price target on shares of Personalis from $18.00 to $14.00 in a research note on Thursday, May 5th. Finally, Zacks Investment Research upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, April 23rd.

In other news, CFO Aaron Tachibana sold 4,511 shares of the business’s stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $10.18, for a total transaction of $45,921.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Stephen Michael Moore sold 5,733 shares of the business’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $5.53, for a total transaction of $31,703.49. Following the transaction, the general counsel now owns 76,381 shares of the company’s stock, valued at $422,386.93. The disclosure for this sale can be found here. Insiders have sold a total of 10,715 shares of company stock worth $82,420 in the last three months. Insiders own 5.80% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in PSNL. Invesco Ltd. grew its position in shares of Personalis by 72.6% during the 2nd quarter. Invesco Ltd. now owns 15,749 shares of the company’s stock valued at $399,000 after purchasing an additional 6,623 shares in the last quarter. Wells Fargo & Company MN grew its position in Personalis by 97.4% in the second quarter. Wells Fargo & Company MN now owns 45,492 shares of the company’s stock worth $1,152,000 after acquiring an additional 22,446 shares in the last quarter. SG Americas Securities LLC purchased a new position in Personalis in the third quarter worth $515,000. Raymond James & Associates grew its position in Personalis by 5.4% in the third quarter. Raymond James & Associates now owns 43,088 shares of the company’s stock worth $829,000 after acquiring an additional 2,191 shares in the last quarter. Finally, Advisor Group Holdings Inc. grew its position in Personalis by 41.1% in the third quarter. Advisor Group Holdings Inc. now owns 3,920 shares of the company’s stock worth $75,000 after acquiring an additional 1,142 shares in the last quarter. Hedge funds and other institutional investors own 86.47% of the company’s stock.

NASDAQ:PSNL opened at $4.80 on Friday. The firm has a market cap of $218.16 million, a price-to-earnings ratio of -2.64 and a beta of 1.71. Personalis has a 52 week low of $3.97 and a 52 week high of $28.47. The firm has a 50-day moving average price of $7.05 and a two-hundred day moving average price of $11.10.

Personalis (NASDAQ:PSNLGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.06). Personalis had a negative net margin of 101.49% and a negative return on equity of 25.70%. During the same quarter in the previous year, the business posted ($0.29) earnings per share. Analysts expect that Personalis will post -2.52 earnings per share for the current year.

About Personalis (Get Rating)

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.

Recommended Stories

Analyst Recommendations for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.